Shares of ZIOPHARM Oncology Inc. (NASDAQ:ZIOP) have been given a consensus rating of “Hold” by the six analysts that are currently covering the stock, Marketbeat Ratings reports. Two equities research analysts have rated the stock with a sell rating, one has given a hold rating and three have given a buy rating to the company. The average 12-month price objective among brokers that have issued ratings on the stock in the last year is $5.50.

Several equities analysts recently issued reports on the company. BidaskClub upgraded ZIOPHARM Oncology from a “hold” rating to a “buy” rating in a research report on Wednesday, November 28th. Raymond James upgraded ZIOPHARM Oncology from a “market perform” rating to an “outperform” rating and set a $5.00 price target on the stock in a research report on Thursday, November 15th. Finally, HC Wainwright set a $6.00 price target on ZIOPHARM Oncology and gave the stock a “buy” rating in a research report on Tuesday, November 13th.

ZIOP traded down $0.19 on Wednesday, hitting $3.15. 1,641,865 shares of the company were exchanged, compared to its average volume of 2,146,355. ZIOPHARM Oncology has a 12 month low of $1.90 and a 12 month high of $5.24. The firm has a market cap of $476.97 million, a price-to-earnings ratio of -5.94 and a beta of 1.94.

ZIOPHARM Oncology (NASDAQ:ZIOP) last posted its quarterly earnings results on Friday, November 9th. The biotechnology company reported ($0.13) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.11) by ($0.02). On average, equities research analysts anticipate that ZIOPHARM Oncology will post -0.51 EPS for the current fiscal year.

A number of institutional investors and hedge funds have recently bought and sold shares of ZIOP. Northern Trust Corp grew its position in shares of ZIOPHARM Oncology by 2.7% in the 2nd quarter. Northern Trust Corp now owns 1,623,297 shares of the biotechnology company’s stock worth $4,902,000 after buying an additional 42,905 shares during the last quarter. BlackRock Inc. grew its position in shares of ZIOPHARM Oncology by 8.5% in the 2nd quarter. BlackRock Inc. now owns 9,167,740 shares of the biotechnology company’s stock worth $27,686,000 after buying an additional 717,804 shares during the last quarter. First Hawaiian Bank bought a new stake in shares of ZIOPHARM Oncology in the 3rd quarter worth approximately $333,000. Bank of America Corp DE grew its position in shares of ZIOPHARM Oncology by 198.1% in the 2nd quarter. Bank of America Corp DE now owns 99,565 shares of the biotechnology company’s stock worth $301,000 after buying an additional 201,063 shares during the last quarter. Finally, MetLife Investment Advisors LLC grew its position in shares of ZIOPHARM Oncology by 77.1% in the 2nd quarter. MetLife Investment Advisors LLC now owns 65,990 shares of the biotechnology company’s stock worth $199,000 after buying an additional 28,734 shares during the last quarter. Institutional investors and hedge funds own 40.07% of the company’s stock.

ZIOPHARM Oncology Company Profile

ZIOPHARM Oncology, Inc, a biotechnology company, focuses on acquiring, developing, and commercializing a portfolio of immuno-oncology therapies for treating heterogenous solid tumors and unknown antigens. The company develops two immuno-oncology platform technologies, including Controlled IL-12, which delivers interleukin 12 or IL-12, a master regular of the immune system, in a controlled and safe manner to focus the patient's immune system to cancer; and Sleeping Beauty (SB), which is based on the genetic engineering of T-cells using the (SB) system to rapidly reprogram T-cells outside of the body for infusion.

Featured Story: Do Tariffs Work?

Receive News & Ratings for ZIOPHARM Oncology Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ZIOPHARM Oncology and related companies with MarketBeat.com's FREE daily email newsletter.